|
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Tech-only, Leukemia/Lymphoma Evaluation (NY)
Test Code37731
CPT Codes
88184, 88185 (x21)<br><strong>Restricted Client Code</strong><br><strong>This test code is for New York patient testing. For non-New York patient testing, use test code 91346</strong>
Includes
Additional markers may be performed based on the pathologist review. These markers will be performed at an additional charge (CPT code(s): 88185 for each additional marker).
Preferred Specimen
4 mL whole blood collected in a sodium heparin (green-top) tube, ACD-A (yellow-top) tube, EDTA (lavender-top) tube or
3 mL bone marrow collected in a sodium heparin (green-top) tube, ACD-A (yellow-top) tube, EDTA (lavender-top) tube or
>0.3 cm of fresh tissue in a sterile plastic container with RPMI 1640 enriched with FBS (10%FBS RPMI)
Minimum Volume
3 mL whole blood • 1 mL bone marrow
Other Acceptable Specimens
Bone marrow collected in a Pediatric heparin tube • Any body fluids (see instructions)
Instructions
Whole blood and bone marrow: The tube must be kept at room temperature and shipped to the lab immediately.
Tissue: Any tissue type is acceptable. Tissue size is dependent upon leukocyte cellularity. Ship tissue in a sterile plastic container with RPMI 1640 enriched with FBS (10% FBS RPMI). Absolutely no fixative should be added. Refrigerate and ship immediately.
Body fluids: Any body fluid is acceptable. Sample size is dependent upon cellularity of the sample. Place fluid in sterile, plastic container. Absolutely no fixative should be added. Refrigerate and ship immediately.
Do not freeze. Send specimen to testing lab for viability determination. Do not reject.
Note: Additional markers may be performed based on the pathologist review. These markers will be performed at an additional charge. Any request for additional marker(s) must be communicated to laboratory within 48 hours of submitting sample and will delay results.
A clinical indication and specimen source are required with each specimen. If available, submit CBC report with differential.
Because of the critical nature of these specimens, the laboratory will attempt to process all specimens received, regardless of age of specimen. Specimens received frozen or in fixative will be rejected.
Tissue: Any tissue type is acceptable. Tissue size is dependent upon leukocyte cellularity. Ship tissue in a sterile plastic container with RPMI 1640 enriched with FBS (10% FBS RPMI). Absolutely no fixative should be added. Refrigerate and ship immediately.
Body fluids: Any body fluid is acceptable. Sample size is dependent upon cellularity of the sample. Place fluid in sterile, plastic container. Absolutely no fixative should be added. Refrigerate and ship immediately.
Do not freeze. Send specimen to testing lab for viability determination. Do not reject.
Note: Additional markers may be performed based on the pathologist review. These markers will be performed at an additional charge. Any request for additional marker(s) must be communicated to laboratory within 48 hours of submitting sample and will delay results.
A clinical indication and specimen source are required with each specimen. If available, submit CBC report with differential.
Because of the critical nature of these specimens, the laboratory will attempt to process all specimens received, regardless of age of specimen. Specimens received frozen or in fixative will be rejected.
Transport Container
See Collection Instructions
Transport Temperature
Whole blood and bone marrow: Room temperature
Tissue and body fluids: Refrigerated (cold packs)
Tissue and body fluids: Refrigerated (cold packs)
Specimen Stability
Whole blood or bone marrow
Room temperature: 72 hours
Refrigerated: Unacceptable
Frozen: Unacceptable
Tissue or body fluid
Room temperature: 72 hours
Refrigerated: 72 hours
Frozen: Unacceptable
Room temperature: 72 hours
Refrigerated: Unacceptable
Frozen: Unacceptable
Tissue or body fluid
Room temperature: 72 hours
Refrigerated: 72 hours
Frozen: Unacceptable
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
See Collection Instructions
Methodology
Flow Cytometry (FC)
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Set up: Daily; Report available: 1 day
Reference Range
See Laboratory Report
Clinical Significance
Technical-only flow cytometry services utilizing a 22-marker panel for evaluation of blood, bone marrow, tissue or body fluids for lymphoid or myeloid disorders. Includes antibodies directed against CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11c, CD13, CD19, CD20, CD23, CD33, CD34, CD38, CD45, CD56, CD64, CD117, HLA-DR, kappa, and lambda.